Analysis of oncogenic EWS-FLI1 pathways via RNAi
|
||
| 16067-B12 | |
Analysis of oncogenic EWS-FLI1 pathways via RNAi |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Peer-reviewed Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Kovar et al., Semin Cancer Biol 2003;13:275-281 EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin Siligan et al., Oncogene 2005; 24(15):2512-24 Context matters: The hen or egg problem in Ewing's sarcoma. Kovar H., Semin Cancer Biol 2005;15:189-196. Ewing's Sarcoma Family of Tumors: Current Management Bernstein et al., Oncologist 2006;11:503-519 Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells Kreppel et al., Oncogene. 2006 May 4;25(19):2795-800 Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Mit Unterstützung vom |
  |